Login to Your Account



Minerva heading to pivotal study in schizophrenia, also hammers out MDD win

By Randy Osborne
Staff Writer

Thursday, May 26, 2016

Positive phase IIb data with MIN-101 in schizophrenia paves the way to pivotal testing and gives patients hope for their negative symptoms, Minerva Neurosciences Inc. spokesman William Boni told BioWorld Today.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription